"We are just beginning to understand the power of the human genome and the profound opportunities ahead. "The face of healthcare is rapidly changing, and I'm delighted to become part of a company at the forefront of that change," said Frank. "As Illumina's impact is increasingly felt in clinical healthcare, it is critically important to actively engage with key government and industry stakeholders on how the power and impact of genomics can better serve patients on a global scale."įrank will directly advise the company's leadership, including its executive team and Board of Directors, offering expertise and ongoing assessment of the geopolitical and policy implications impacting Illumina's business strategies. "John's deep, global government affairs and public policy experience are invaluable as we work to increase patients' access to genomics around the world," said Francis deSouza, Chief Executive Officer. The goal of aggregating these functions under John's leadership is to combine and amplify the voices of Illumina's critical advocacy groups to drive meaningful change for patients.
In this role, he will have strategic oversight for Illumina's global government affairs and public policy operations, its Corporate Social Responsibility efforts, all patient advocacy initiatives, and the privacy and ethics office.
As Illumina's Chief Public Affairs Officer, John will be the company's top strategic adviser and decision maker on government affairs and public policy matters.
0 kommentar(er)
